This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Related letters  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Medical Practice  • Medical Ethics  • Neurology  • Alzheimer Disease  • Cognitive Disorders  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The study by Dr Ross and colleagues¹ and the Editorial by Drs DeAngelis and Fontanarosa² open a long overdue debate on ghostwriting and guest authorship. The case of rofecoxib is likely just one example of a widespread practice. The Editorial focuses mostly on the direct financial aspects of the guest authorship (ie, payment by the industry or by its proxies) and points out that guest authorship is unprofessional and demeaning to the medical profession and to scientific research. However, the potential direct financial gain is not the only benefit of guest authorship. Other benefits include prestige and increasing the number of an academic author's publications. The publications are used in the process of promotion and in the evaluation for merit increases and/or salary bonuses (which, although relatively small for some prominent authors, may be significant for others). Thus, guest authors are receiving an unfair advantage over many . . . [Full Text of this Article]

Richard Balon, MD
rbalon@wayne.edu
Department of Psychiatry and Behavioral Neurosciences
Wayne State University School of Medicine
Detroit, Michigan

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation
, , , and
JAMA. ;299():1800-1812.
FULL TEXT  

Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence
and
JAMA. ;299():1833-1835.
FULL TEXT  

RELATED LETTERS

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():900-900.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():900-901.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():901-901.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():901-901.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
, , and
JAMA. ;300():901-902.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():902-903.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():903-903.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():903-904.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():904-904.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
and
JAMA. ;300():904-904.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
, , and
JAMA. ;300():904-905.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
and
JAMA. ;300():905-906.
FULL TEXT